These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1525595)

  • 61. Tamoxifen and ICI 182,780 interactions with thyroid hormone in the ovariectomized-thyroidectomized rat.
    Dipippo VA; Powers CA
    J Pharmacol Exp Ther; 1997 Apr; 281(1):142-8. PubMed ID: 9103491
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 17 beta-estradiol prevents osteopenia in the oophorectomized rat treated with cyclosporin-A.
    Joffe I; Katz I; Jacobs T; Stein B; Takizawa M; Liu C; Berlin J; Epstein S
    Endocrinology; 1992 Mar; 130(3):1578-86. PubMed ID: 1537307
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity.
    Branham WS; Fishman R; Streck RD; Medlock KL; De George JJ; Sheehan DM
    Biol Reprod; 1996 Jan; 54(1):160-7. PubMed ID: 8838013
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Distribution of luteinizing hormone-releasing hormone receptors in the rat ovary.
    Séguin C; Pelletier G; Dubé D; Labrie F
    Regul Pept; 1982 Sep; 4(4):183-90. PubMed ID: 6293004
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Skeletal response of ovariectomized rats to low and high doses of 17 beta-estradiol.
    Kalu DN; Liu CC; Salerno E; Hollis B; Echon R; Ray M
    Bone Miner; 1991 Sep; 14(3):175-87. PubMed ID: 1932891
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
    Martel C; Picard S; Richard V; Bélanger A; Labrie C; Labrie F
    J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):45-56. PubMed ID: 11074355
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat.
    Mizutani T; Sakata M; Terakawa N
    Int J Fertil Menopausal Stud; 1995; 40(2):106-11. PubMed ID: 7599657
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibitory effects of a luteinizing-hormone-releasing hormone agonist implant on ovine fetal gonadotrophin secretion and pituitary sensitivity to luteinizing-hormone-releasing hormone.
    Brooks AN; McNeilly AS
    J Reprod Fertil; 1992 Nov; 96(2):785-92. PubMed ID: 1339858
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The gonadotropin-releasing hormone (GnRH) agonist-induced initial rise of bioactive LH and testosterone can be blunted in a dose-dependent manner by GnRH antagonist in the non-human primate.
    Sharma OP; Weinbauer GF; Behre HM; Nieschlag E
    Urol Res; 1992; 20(5):317-21. PubMed ID: 1455564
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The effects of GnRH agonist on steroidogenesis in the rat ovary].
    Yago N
    Nihon Naibunpi Gakkai Zasshi; 1994 Aug; 70(6):543-54. PubMed ID: 7958104
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
    Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
    J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potentiating effect of buserelin acetate, an LHRH agonist, on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats.
    Maezawa H; Komatsu H; Kawaoi A; Ueno A
    Int J Urol; 1997 Jul; 4(4):411-6. PubMed ID: 9256333
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effect of olpadronate in ovariectomized thyroxine-treated rats.
    Zeni S; Gomez-Acotto C; Mautalen C
    Bone; 1997 Oct; 21(4):329-33. PubMed ID: 9315336
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
    Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
    Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pituitary-testicular function is suppressed by an LHRH antagonist but not by an LHRH agonist in the marmoset monkey.
    Lunn SF; Dixson AF; Sandow J; Fraser HM
    J Endocrinol; 1990 May; 125(2):233-9. PubMed ID: 2165119
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
    Jordan VC; Gosden B
    Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes in pituitary responsiveness to LH-releasing hormone after acute buserelin treatment: a time-course and dose-response study.
    Heather JD; Whitehead SA
    J Endocrinol; 1985 Jul; 106(1):27-30. PubMed ID: 3926929
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reversible increase in energy deposition following castration induced by a gonadotropin releasing hormone agonist.
    Richard D; DeKoninck P; Lemay A; Rivest S
    Int J Obes; 1991 Feb; 15(2):155-61. PubMed ID: 1904053
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
    Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma.
    Ito M; Sakoda Y; Okamura H
    Endocrinol Jpn; 1990 Dec; 37(6):907-13. PubMed ID: 1966283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.